Search results
Results From The WOW.Com Content Network
Losartan should not be taken by people who are diabetic and taking aliskiren. [3] Anemia may occur, due to inhibition of the renin–angiotensin system. [17] As with other angiotensin receptor blockers, losartan may injure the liver, although this effect appears to be rare. [18]
Losartan, the first ARB. Angiotensin II receptor blockers (ARBs), formally angiotensin II receptor type 1 (AT 1) antagonists, [1] also known as angiotensin receptor blockers, [2] [3] angiotensin II receptor antagonists, or AT 1 receptor antagonists, are a group of pharmaceuticals that bind to and inhibit the angiotensin II receptor type 1 (AT 1) and thereby block the arteriolar contraction and ...
Losartan/hydrochlorothiazide, sold under the brand name Hyzaar among others, is a fixed-dose combination medication used to treat high blood pressure when losartan is not sufficient. [1] [2] It consists of losartan, an angiotensin II receptor blocker; and hydrochlorothiazide, a thiazide diuretic. [1] [2] It is taken by mouth. [1] [2]
The fundamental goal of treatment should be the prevention of the important endpoints of hypertension, such as heart attack, stroke and heart failure. Patient age, associated clinical conditions and end-organ damage also play a part in determining dosage and type of medication administered. [ 3 ]
You may improve this article, discuss the issue on the talk page, or create a new article, as appropriate. ( December 2023 ) ( Learn how and when to remove this message ) Commonly prescribed drugs are drugs that are frequently provided by doctors in a prescription to treat a certain disease.
ACV may interact with medications affecting potassium or insulin, such as diuretics like furosemide, insulin, and certain blood pressure medications like lisinopril and losartan, says Routhenstein ...
Aliskiren (brand names Tekturna and Rasilez) is the first in a class of drugs called direct renin inhibitors.It is used for essential (primary) hypertension. [2] While used for high blood pressure, other better studied medications are typically recommended due to concerns of higher side effects and less evidence of benefit.
URAT1 is the central mediator in the transport of uric acid from the kidney into the blood. In some persons with loss-of-function mutations of URAT1, the uricosurics benzbromarone and losartan had no effect, suggesting these drugs act on URAT1 in vivo. [1] Thus, uricosuric drugs may be candidates for management in a personalized medicine model.